Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 11/20 | 0.63 |
| ▸ | CDK2 | P24941 | 9/20 | 0.63 |
| ▸ | CDK1 | P06493 | 6/20 | 0.63 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.63 |
| ▸ | CCNH | P51946 | 5/20 | 0.63 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.63 |
| ▸ | CDK9 | P50750 | 4/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.63 |
| ▸ | CDK4 | P11802 | 2/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.63 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24793439 | 0.91 | CDK2 (0.60) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL31304770 | 0.91 | CDK2 (0.60) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL30083538 | 0.88 | CDK2 (0.55) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL24793441 | 0.88 | CDK2 (0.55) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL20848283 | 0.87 | CDK7 (0.48) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL20848281 | 0.87 | CDK7 (0.59) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL24793455 | 0.86 | CDK2 (0.71) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL20848170 | 0.83 | CDK2 (0.64) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL20839004 | 0.83 | CDK2 (0.64) | CDK7CDK2CDK1CCNE1CCNH | |
| SCHEMBL30718553 | 0.83 | CDK2 (0.64) | CDK7CDK2CDK1CCNE1CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | Carrick Therapeutics Limited (IE) | 2024-01-02 | — | — | US | disclosed |
| CN-111566106-B | Compounds as CDK inhibitors | 卡里克治疗有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-3684769-B1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CARRICK THERAPEUTICS LTD (IE) | 2022-01-12 | — | — | EP | disclosed |
| EP-3684769-B1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CARRICK THERAPEUTICS LTD (IE) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021122745-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2021-06-24 | — | — | WO | disclosed |
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | Carrick Therapeutics Limited (IE) | 2020-11-05 | — | — | US | disclosed |
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | Carrick Therapeutics Limited (IE) | 2020-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345736-A1 | 4-[[(7-AMINOPYRAZOLO[1,5-A]PYRIMIDIN-5-YL)AMINO]METHYL]PIPERIDIN-3-OL COMPOUNDS AS CDK INHIBITORS | CDK10, CDK1, CDK20 | CDK7 21/4885CDK2 6/4885CDK1 2/4885 |
| US-11857552-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors | CDK10, CDK1, CDK20 | CDK7 21/4885CDK2 6/4885CDK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.